Clinical tests start in Ebola vaccine race | Fin24
  • Mpumalanga Mine

    Constitutional Court rejects coal mining company’s attempt to appeal – but the saga isn’t over.

  • Audit Outcomes

    Turnaround plans had virtually no impact for ailing parastatals, the Auditor-General has found.

  • Battery Power

    Gordhan: Government intends to sign off soon on a "world class" battery storage project.


Clinical tests start in Ebola vaccine race

Jan 06 2015 16:46

London - Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.

The start of the Phase I study in Britain, which had been expected about now, marks further progress in the race to develop a vaccine against a disease that has killed more than 8 000 people in West Africa since last year.

Two other experimental vaccines, one from GlaxoSmithKline and a rival from NewLink and Merck, are already in clinical development, but the J&J vaccine offers a different approach since it involves two separate injections.

Brought under control

US-based J&J said on Tuesday it had produced enough vaccine to treat more than 400 000 people, which could be used in large-scale clinical trials by April, and a total of two million courses would be available in 2015. Previously, J&J expected more than one million courses this year.

It also now predicts it can make enough vaccine for five million treatments, if required, over a 12- to 18-month period.

Just how much Ebola vaccine will be needed depends on how quickly the epidemic in Liberia, Sierra Leone and Guinea is brought under control and declines.

Currently, experts project demand at anywhere between 100 000 and 12 million doses.

The first volunteers have received initial injections in Oxford, where 72 healthy subjects will get different regimens involving various combinations of the vaccine components or a placebo.

Additional clinical studies are planned in the United States later this month and soon after in Africa, where volunteers will receive the vaccine in Kenya, Uganda and Tanzania.

More strategic option

Phase I trials are designed primarily to test safety but may also indicate whether vaccines produce a good immune response.

The GSK and NewLink vaccines have been tested initially as single shots, although there is growing debate as to whether two-stage vaccination might be a more strategic option, since it is likely to provide better protection. The downside is that it would make mass immunisation more complicated.

Shares in Bavarian Nordic, which received investment from J&J last year to accelerate production, rose 3.9% to their highest level in four years.

Although it is too early to say how much a vaccine might cost, the GAVI global vaccines alliance announced last month it was committing up to $300m to buy Ebola shots.

glaxosmithkline  |  vaccine  |  ebola outbreak


Read Fin24’s Comments Policy publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Company Snapshot

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...

Voting Booth

What do you think about private healthcare in SA?

Previous results · Suggest a vote